Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEDVsDox for recurrent EGFR-expressing glioblastoma multiforme
ACTRN12613000297729Phase 2Terminated
- Sponsor
- EnGeneIC
- Start
- Feb 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in glioblastoma (GBM), sponsored by EnGeneIC. Primary endpoint: Six-month progression-free survival. Started Feb 2013; status: terminated.
02
Drugs
doxorubicin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ACTRN12613000297729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000297729.